Qiagen LLC Reagents and Consumables

This is a Notice of Intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.

The National Institute of Health/Clinical Center/Office of Purchasing and Contracts intends to award a firm fixed price contract to Qiagen LLC, Germantown, MD 20874 for reagent kits and consumables.

Qiagen LLC is the only vendor/manufacturer that can provide the reagent kits and consumables used to isolate DNA and RNA from various cell populations from peripheral blood of stem cell transplant patients or patients with hematological disorder and are specifically used with already existing instrumentation within The Department of Laboratory Medicine of the Clinical Center. The testing done using these reagents is for basic clinical care, research, and advancing the science and applications associated with diagnostic analysis of hematological disorders such as Myeloproliferative diseases and Chimerism monitoring after Allogenic Stem Cell transplant. These reagents have been fully validated for use in BCR-ABL fusion assay and JAK2 mutation assay. Switching to another system would entail lengthy validations and would alter current results of NIH protocols.

The estimated product list is attached to this notice and titled – Attachment 1 – List of Supplies 25-000149. The government reserves the right to increase quantities pursuant to FAR 52.217-6.

This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1).  For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting o icer determines that the circumstance of the contract action deem only one source reasonably available.  Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

Interested concerns capable of providing the same or similar products or services as described in this notice may submit a capability statement outlining their capabilities.

Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.

The North American Industry Classification System (NAICS) code for this acquisition is 325414 - BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING large business standard size of 1,250 employees.

Each response should include the following Business Information:

a. SAM UEI.

b. Company Name, address, POC, Phone and Email address

c. Current GSA Schedules or NAICS codes appropriate to this Award.

d. Type of Company (i.e., small business, 8(a), woman owned, hubZone, veteran owned, etc.) as validated in System For Award Management (SAM). All offerors must register on the SAM located at http://www.sam.gov/portal/SAM/#1

e. Capability Statement

Comments to this announcement may be submitted to the Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Kimala Winfield, kimala.winfield@nih.gov or Malinda Dehner, dehnerm@cc.nih.gov by the due date and time marked in this notice